» Articles » PMID: 19903741

Positive Regulation of Spondin 2 by Thyroid Hormone is Associated with Cell Migration and Invasion

Overview
Specialties Endocrinology
Oncology
Date 2009 Nov 12
PMID 19903741
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The thyroid hormone 3,3',5-triiodo-L-thyronine (T(3)) regulates growth, development, and differentiation processes in animals. These activities are mediated by the nuclear thyroid hormone receptors (TRs). Microarray analyses were performed previously to study the mechanism of regulation triggered by T(3) treatment in hepatoma cell lines. The results showed that spondin 2 was regulated positively by T(3). However, the underlying mechanism and the physiological role of T(3) in the regulation of spondin 2 are not clear. To verify the microarray results, spondin 2 was further investigated using semi-quantitative reverse transcription-PCR and western blotting. After 48 h of T(3) treatment in the HepG2-TR alpha 1#1 cell line, spondin 2 mRNA and protein levels increased by 3.9- to 5.7-fold. Similar results were observed in thyroidectomized rats. To localize the regulatory region in spondin 2, we performed serial deletions of the promoter and chromatin immunoprecipitation assays. The T(3) response element on the spondin 2 promoter was localized in the -1104/-1034 or -984/-925 regions. To explore the effect of spondin 2 on cellular function, spondin 2 knockdown cell lines were established from Huh7 cells. Knockdown cells had higher migration ability and invasiveness compared with control cells. Conversely, spondin 2 overexpression in J7 cells led to lower migration ability and invasiveness compared with control cells. Furthermore, this study demonstrated that spondin 2 overexpression in some types of hepatocellular carcinomas is TR dependent. Together, these experimental findings suggest that spondin 2, which is regulated by T(3), has an important role in cell invasion, cell migration, and tumor progression.

Citing Articles

The Prognostic Significance of TRs in Hepatocellular Carcinoma: Insights from TCGA and GEO Databases.

Zhou H, Wang W, Liang R, Zhu R, Cao J, Sun C Biomark Insights. 2025; 20:11772719251315321.

PMID: 39866810 PMC: 11765354. DOI: 10.1177/11772719251315321.


The biological functions and related signaling pathways of SPON2.

Zhang J, Liu G, Liu Y, Yang P, Xie J, Wei X Front Oncol. 2024; 13:1323744.

PMID: 38264743 PMC: 10803442. DOI: 10.3389/fonc.2023.1323744.


Comprehensive analysis of the oncogenic and immunological role of SPON2 in human tumors.

Tang J, Huang Q, Li X, Gu S Medicine (Baltimore). 2023; 102(37):e35122.

PMID: 37713832 PMC: 10508437. DOI: 10.1097/MD.0000000000035122.


The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.

Deligiorgi M, Trafalis D J Clin Med. 2022; 11(12).

PMID: 35743483 PMC: 9224934. DOI: 10.3390/jcm11123417.


The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research.

Deligiorgi M, Trafalis D Int J Mol Sci. 2022; 23(1).

PMID: 35008863 PMC: 8745569. DOI: 10.3390/ijms23010436.